Vitamodo School · Bundle 4: Antipsychiatry — The Critique Analyzed · Brochure 5 of 10 · Version 1.0
Andris Saulitis, MD
For those who: have encountered the antidepressant debate — through reading, through your own prescription, through someone you love — and want to engage with both sides at their careful level.
Not for those who: want a verdict on antidepressants as a category. They are not one category, and the verdict differs substantially by condition, severity, and patient.
What this is — the clinical reality
There is, in public discussion, an antidepressant debate. There is also, in the careful clinical and academic literature, a substantially more layered conversation that bears only a partial resemblance to its popular form. The public version is conducted as a binary: antidepressants work, or antidepressants do not work; antidepressants are over-prescribed, or antidepressants are life-saving; chemical imbalance is science, or chemical imbalance is marketing. The careful version is conducted on multiple specific questions, each with its own evidence base, each with answers that vary substantially by patient population, by severity, by indication, and by duration of treatment.
This brochure is for the reader who has encountered the debate — through Robert Whitaker's Anatomy of an Epidemic, through Irving Kirsch's meta-analyses, through Joanna Moncrieff's drug-centred model, through opposing arguments from the mainstream psychiatric press, through their own experience of taking or stopping one of these medications, or through the experience of someone they love. It is for the reader who wants to know what each side actually argues, where the careful evidence sits, and how a thoughtful person can hold the picture in the absence of the simple answer the public conversation keeps demanding.
A note before we go further. Antidepressant is not a single thing. The selective serotonin reuptake inhibitors (SSRIs — fluoxetine, sertraline, citalopram, paroxetine, and others), the serotonin-norepinephrine reuptake inhibitors (SNRIs — venlafaxine, duloxetine), the older tricyclic antidepressants, the monoamine oxidase inhibitors, the newer agents (bupropion, mirtazapine, vortioxetine, esketamine) — these are different classes with different mechanisms, different evidence bases, different side-effect profiles, and different clinical indications. The public debate frequently treats them as one category. The careful conversation does not. This brochure addresses the SSRI/SNRI debate principally, because that is where the public argument lives.
Three frames carry the debate.
The first frame is what the critique actually says. The careful critique — Whitaker on long-term outcomes, Kirsch on effect-size meta-analyses, Moncrieff on the disease-centred model, and the substantial subsequent critical literature — makes a set of specific arguments that have, in many cases, accumulated more support than the mainstream profession initially conceded. These include: that the placebo-controlled effect of SSRIs in mild-to-moderate depression is modest, often substantially smaller than the marketing of these medications implied; that publication bias and selective trial reporting inflated the apparent effect for years; that the chemical-imbalance story — low serotonin causes depression — was always weaker than its public deployment suggested, and that the recent careful meta-review (Moncrieff and colleagues, 2022) confirms what specialists had long suspected, that the serotonin model is not supported by the evidence at the level it has been popularly presented; that discontinuation symptoms ranged from minor to severe and were systematically downplayed in patient information for decades; that the long-term outcomes of chronic SSRI use have been poorly studied, and what data exists raises questions the profession has been slow to engage with; that the prescribing of these medications expanded substantially beyond the populations in which they were originally tested, partly driven by industry marketing and primary-care normalisation rather than by clinical evidence. These are not antipsychiatric talking points; these are positions for which the careful critical literature has built a substantial case.